Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Mar 2023

Zhong G C, Yu X N, Li J, Chen C Y

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD79 Antigens
Share to Leg
Share to Lymphoma, Large B-Cell, Diffuse
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Myeloid Differentiation Factor 88

Share to Rituximab

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 37356991
DOI: 10.3760/cma.j.issn.0253-2727.2023.03.015
PMCID: PMC10119723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].PMID 37356991Read ↗

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.Semantic proximity Read ↗

MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSemantic proximity Read ↗

Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.Semantic proximity Read ↗

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.Semantic proximity Read ↗

High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.Semantic proximity Read ↗

Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.Semantic proximity Read ↗

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.Semantic proximity Read ↗

MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell LymphomaSemantic proximity Read ↗

TdT-positive primary cutaneous diffuse large B-cell lymphoma, leg type phenotypically mimicking B-lymphoblastic lymphoma.Semantic proximity Read ↗

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.Semantic proximity Read ↗

Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2.Semantic proximity Read ↗

Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi EraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.